Trial Outcomes & Findings for Contingency Management to Promote Smoking Abstinence in Cancer Patients (NCT NCT04605458)
NCT ID: NCT04605458
Last Updated: 2026-08-18
Results Overview
Abstinence will be defined by 7 days by self-report of no tobacco products, confirmed by CO breath test less than or equal to 4ppm and/or urine anabasine levels less than or equal to 2 ng/ml
COMPLETED
NA
282 participants
Changes between the study intake appointment to day of surgery, up to five weeks apart
2026-08-18
Participant Flow
Participant milestones
| Measure |
Contingency Management
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
|
Standard Care
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
|
|---|---|---|
|
Overall Study
STARTED
|
139
|
143
|
|
Overall Study
Completed Surgical Outcome
|
101
|
109
|
|
Overall Study
Completed 3 Month Follow-up
|
71
|
66
|
|
Overall Study
COMPLETED
|
69
|
75
|
|
Overall Study
NOT COMPLETED
|
70
|
68
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Contingency Management to Promote Smoking Abstinence in Cancer Patients
Baseline characteristics by cohort
| Measure |
Contingency Management
n=139 Participants
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
|
Standard Care
n=143 Participants
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
|
Total
n=282 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
59.4 years
STANDARD_DEVIATION 10.7 • n=298 Participants
|
59.0 years
STANDARD_DEVIATION 9.7 • n=102 Participants
|
59.2 years
STANDARD_DEVIATION 10.2 • n=400 Participants
|
|
Sex: Female, Male
Female
|
79 Participants
n=298 Participants
|
83 Participants
n=102 Participants
|
162 Participants
n=400 Participants
|
|
Sex: Female, Male
Male
|
60 Participants
n=298 Participants
|
60 Participants
n=102 Participants
|
120 Participants
n=400 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=298 Participants
|
2 Participants
n=102 Participants
|
3 Participants
n=400 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=298 Participants
|
0 Participants
n=102 Participants
|
0 Participants
n=400 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=298 Participants
|
0 Participants
n=102 Participants
|
0 Participants
n=400 Participants
|
|
Race (NIH/OMB)
Black or African American
|
25 Participants
n=298 Participants
|
44 Participants
n=102 Participants
|
69 Participants
n=400 Participants
|
|
Race (NIH/OMB)
White
|
107 Participants
n=298 Participants
|
91 Participants
n=102 Participants
|
198 Participants
n=400 Participants
|
|
Race (NIH/OMB)
More than one race
|
4 Participants
n=298 Participants
|
3 Participants
n=102 Participants
|
7 Participants
n=400 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=298 Participants
|
3 Participants
n=102 Participants
|
5 Participants
n=400 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
4 Participants
n=298 Participants
|
3 Participants
n=102 Participants
|
7 Participants
n=400 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
133 Participants
n=298 Participants
|
140 Participants
n=102 Participants
|
273 Participants
n=400 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=298 Participants
|
0 Participants
n=102 Participants
|
2 Participants
n=400 Participants
|
|
Cigarettes Smokerd Per day, mean
|
15 CPD
STANDARD_DEVIATION 8.7 • n=298 Participants
|
13.6 CPD
STANDARD_DEVIATION 8.4 • n=102 Participants
|
14.3 CPD
STANDARD_DEVIATION 8.6 • n=400 Participants
|
PRIMARY outcome
Timeframe: Changes between the study intake appointment to day of surgery, up to five weeks apartPopulation: Primary study abstinence rate was measures using self-report for past 7 days, Carbon Monoxide Breath Monitoring and/or Anabasine testing. This sample is limited to participant who had surgery performed within the study window, completed self-reported nicotine use data and provided a biochemical sample.
Abstinence will be defined by 7 days by self-report of no tobacco products, confirmed by CO breath test less than or equal to 4ppm and/or urine anabasine levels less than or equal to 2 ng/ml
Outcome measures
| Measure |
Contingency Management
n=71 Participants
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
|
Standard Care
n=77 Participants
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
|
|---|---|---|
|
Abstinence Rates as Assessed by Self-report for Past 7 Days, Carbon Monoxide Breath Monitoring and/or Anabasine Testing
|
39 participants
|
27 participants
|
SECONDARY outcome
Timeframe: Three months after surgery datePopulation: Secondary study abstinence rate was measures using self-report for past 7 days, Carbon Monoxide Breath Monitoring and/or Anabasine testing. This sample is limited to participant who had surgery performed within the study window, completed self-reported nicotine use data and provided a biochemical sample.
Abstinence will be defined by 7 days by self-report of no tobacco products, confirmed by CO breath test less than or equal to 4ppm and/or urine anabasine levels less than or equal to 2 ng/ml
Outcome measures
| Measure |
Contingency Management
n=56 Participants
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
|
Standard Care
n=49 Participants
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
|
|---|---|---|
|
Abstinence Rates as Assessed by Self-report for Past 7 Days, Carbon Monoxide Breath Monitoring and/or Anabasine Testing
|
19 Participants
|
12 Participants
|
SECONDARY outcome
Timeframe: Six months after surgery datePopulation: Secondary study abstinence rate was measures using self-report for past 7 days, Carbon Monoxide Breath Monitoring and/or Anabasine testing. This sample is limited to participant who had surgery performed within the study window, completed self-reported nicotine use data and provided a biochemical sample.
Abstinence will be defined by 7 days by self-report of no tobacco products, confirmed by CO breath test less than or equal to 4ppm and/or urine anabasine levels less than or equal to 2 ng/ml
Outcome measures
| Measure |
Contingency Management
n=66 Participants
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
|
Standard Care
n=65 Participants
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
|
|---|---|---|
|
Abstinence Rates as Assessed by Self-report for Past 7 Days, Carbon Monoxide Breath Monitoring and/or Anabasine Testing
|
24 Participants
|
20 Participants
|
Adverse Events
Contingency Management
Standard Care
Serious adverse events
| Measure |
Contingency Management
n=139 participants at risk
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and monetary payment delivered contingent on abstinence verified by CO breath test.
|
Standard Care
n=143 participants at risk
Participants will receive 3-6 counseling sessions, nicotine patches \& lozenges, and CO breath test monitoring.
|
|---|---|---|
|
General disorders
Death
|
3.6%
5/139 • Number of events 5 • Time frame for adverse event reporting is from the study Baseline time point through the 6-Month follow-up visit; a total duration of 6 months.
Adverse Events were assessed at each study visit and prompted with SAFTEE screening form.
|
2.8%
4/143 • Number of events 4 • Time frame for adverse event reporting is from the study Baseline time point through the 6-Month follow-up visit; a total duration of 6 months.
Adverse Events were assessed at each study visit and prompted with SAFTEE screening form.
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place